Replies to post #108873 on Biotech Values

[ghmm]

That is why you invest in BMRN :-).

I don't fault the company if they partner early they get peanuts not worth the return. I suspect they felt confident in being able to get compelling enough data to attract a strong partner on favorable terms.

[rkrw]

It was nicely in their sweet spot from all their work on Lovenox and obviously they didn't anticipate partnering would be so difficult. M118 inception predates Wheeler fwiw.

Similar comments about choosing a difficult first project were made with Lovenox btw :)

[DewDiligence]

…I have always been puzzled as to why MNTA/Wheeler decided to pursue M118 in the first place without a designated partner from the beginning.

As rkrw said, MNTA’s decision to develop M118 goes back a long way and predates Craig Wheeler’s 2006 hiring by several years.

When the M118 program was started, MNTA had not even submitted the Lovenox ANDA and management surely expected the FDA to approve Lovenox in less than the five years it ended up taking. Consequently, the cost of the M118 development program was not seen at the time as an unduly onerous financial burden.